Tag: Egfr inhibitor

Afatinib is a second-generation tyrosine kinase inhibitor approved for specific non-small cell lung cancer (NSCLC) types. A key to its effectiveness lies in understanding **what is the mechanism of action of afatinib**—its irreversible inhibitory activity against multiple ErbB receptor family targets.

Originally developed by Abgenix Inc., Vectibix (panitumumab) has been manufactured and commercialized by the biopharmaceutical company Amgen Inc. since it acquired Abgenix in 2006. This acquisition gave Amgen full ownership and control over the drug, solidifying its role in bringing this important metastatic colorectal cancer treatment to market.